26.50 USD
▲+0.26+2.79%
盘后 25.78 0.00%
2026-08-03
市值
$2.34B
市盈率
—
EPS
-2.02
股息率
—
52 周区间
12.59 – 47.65
成交量
663.82K
Beta
0.65
目标价
49.00
52W 低 12.5952W 高 47.65
价格走势
公司简介
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Minera...